NEW DELHI - Alembic Pharmaceuticals received final U.S. Food and Drug Administration approval on Nov. 14 for generic binimetinib tablets in 15 mg and 45 mg strengths. The drug treats specific genetic forms of melanoma and non-small cell lung cancer.
Therapeutic Equivalence to Branded Mektovi
The FDA approved Alembic's Abbreviated New Drug Application, finding its tablets therapeutically equivalent to Array BioPharma's reference drug Mektovi (15 mg). Used alongside encorafenib, binimetinib is a kinase inhibitor indicated for unresectable or metastatic melanoma with BRAF V600E or V600K mutations and metastatic non-small cell lung cancer with a BRAF V600E mutation.
180-Day Exclusivity in $282 Million Market
Alembic qualifies for 180 days of generic exclusivity on both strengths as one of the first applicants for 15 mg and the sole first applicant for the new 45 mg strength. "According to IQVIA, Binimetinib tablets have an estimated market size of $282 million for the 12 months ending September 2026, the filing noted."
Cumulative FDA Approvals Reach 248
The clearance brings Alembic's cumulative FDA ANDA total to 248 approvals, comprising 230 final approvals and 18 tentative approvals. Adding a single 45 mg tablet option may also simplify daily dosing for patients taking the combination therapy.


